ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(3Α)-アロプレグナノロン

Allopregnanolone

HCID 92786
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
516-54-1
標準SMILES
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
AURFZBICLPNKBZ-SYBPFIFISA-N
分子式
C21H34O2
平均分子量
318.5 g/mol
単同位体質量
318.25588032

概要

Brexanolone is a 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women. It has a role as an antidepressant, a sedative, an intravenous anaesthetic, a GABA modulator and a human metabolite.

名称と識別子

優先名称
Allopregnanolone
IUPAC
1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
現地名
(3Α)-アロプレグナノロン
英語名
Allopregnanolone
分子式
C21H34O2
分子量
318.49

名称と別名

Allopregnanolone516-54-1BrexanoloneAllotetrahydroprogesterone3alpha-hydroxy-5alpha-pregnan-20-one3alpha,5alpha-THPAllopregnan-3alpha-ol-20-onebrexanolona3alpha-OH DHP3alpha-Hydroxy-5alpha-dihydroprogesteroneS39XZ5QV8YCHEMBL207538
名称をさらに表示
(3Α)-アロプレグナノロンアロプレグナノロン5Α-プレグナン-3Α-オール-20-オンブレキサノロン3α-ヒドロキシ-5α-プレグナ-20-オン3α,5α-テトラヒドロプロゲステロンallo-プレグナン-3α-オール-20-オン1-[(1S,3aS,3bR,5aS,7R,9aS,9bS,11aS)-7-ヒドロキシ-9a,11a-ジメチル-ヘキサデカヒドロ-1H-シクロペンタ[a]フェナントレン-1-イル]エタン-1-オン(+)-3-ジヒドロプロゲステロン3α-ジヒドロプロゲステロン(17S)-3α-ヒドロキシ-5α-プレグナン-20-オンエピアロプレグナノロンアロプレグナン-3α-オール-20-オン20-オキソ-5α-プレグナン-3α-オール3α-ヒドロキシジヒドロプロゲステロンエパロン3α-ヒドロキシ-5α-プレグナン-20-オンエピアロプレグナン-3-オール-20-オン17β-アセチル-5α-アンドロスタン-3α-オールAnlotinib Dihydrochloride(3a)-Allopregnanolone3α-hydroxy-5α-pregnan-20-one1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one(3alpha)-Allopregnanolone3α-hydroxy-5α-pregnan-20-oneAllopregnanolone(Brexanolone)5α-P
CHEBI:50169DEA NO. 2400DTXSID901016239Pregnan-20-one, 3-hydroxy-, (3-alpha,5-alpha)-3 alpha Hydroxy 5 alpha pregnan 20 one3 alpha-Hydroxy-5 alpha-pregnan-20-onealpha-Hydroxy-5 alpha-pregnan-20-one, 3alpha-pregnan-20-one, 3 alpha-Hydroxy-5

データベース識別子

CAS
516-54-1
PubChem CID
92786
DTXSID
DTXSID901016239
ChEMBL
CHEMBL207538
ChEBI
CHEBI:50169
UNII
S39XZ5QV8Y
EC Number
869-372-7
Nikkaji
J6.315K

物性

構造計算による物性

XLogP
4.9
極性表面積
37.3 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
1
重原子数
23
形式電荷
0
複雑度
500

実験および物理化学的性質

Drugs · 2 件

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs · 3 件

Breastfeeding; Lactation; Milk, Human; Antidepressants; Antidepressive Agents; GABA Agents; Hormones; Progesterone Congeners

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point177 °C
Physical DescriptionSolid
Collision Cross Section177.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
176 · 176-178°
比旋光度
87.7 ° · D +87.7° (abs alc)
沸点
431.2 · 431.2±18.0 °C(Predicted)
比重(密度)
1.053 · 1.053±0.06 g/cm3(Predicted)
貯蔵温度
Store at RT
溶解性
20 mg/mL · クロロホルム:20 mg/mL 無色透明
外見
白い固体
酸解離定数(Pka)
15.12 · 15.12±0.70(Predicted)
色
白い
Merck
13 · 13,272
BRN
3211363 · 3211363
安定性
-20 °Cで最大1か月保存できます。 · DMSO溶液またはエタノール溶液で-20°Cで最大1か月保存できます。
InChI
InChI=1/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/s3
InChIKey
AURFZBICLPNKBZ-SYBPFIFISA-N
SMILES
[C@]12([H])CC[C@]3(C)[C@H](CC[C@@]3([H])[C@]1([H])CC[C@@]1([H])C[C@H](O)CC[C@]21C)C(=O)C |&1:0,4,6,9,11,15,18,22,r|
CAS データベース
516 · 516-54-1(CAS DataBase Reference)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS ClassificationNot Classified

危険有害性情報

Regulatory InformationDEA schedule IV controlled substance
Hazard Classes and CategoriesNot Classified

毒性情報

HepatotoxicityIn premarketing studies, liver test abnormalities were uncommon in patients receiving brexanolone (
Adverse EffectsClinical trials have demonstrated brexanolone as generally well-tolerated. The most common adverse effects associated with brexanolone are dizziness, sedation/somnolence, xerostomia, loss of consciousness, and hot flushes.
Toxicity Summary · 1 件

Brexanolone has a rapid onset of action within 60 hours of infusion and has a sustained response for up to 30 days after infusion. Patients in clinical trials were not followed after a 30-day follow-up period, limiting data on toxicity from long-term use. Long-term efficacy of brexanolone, when compared with other antidepressants, is unknown and needs further research.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Brexanolone

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

F
10
wgk
3
rtecs
TU4383000
hs_code
2937900090
safety_code
22-24/25

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein BindingThe plasma protein binding recorded for brexanolone is greater than 99% and was determined to be independent of plasma concentrations.
Pharmacodynamics · 1 件

Brexanolone potentiated GABA-mediated currents from recombinant human GABA(a) receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits. Moreover, it was determined during a Phase 1 randomized, placebo and positive-controlled, double-blind, three-period crossover thorough QT study in 30 healthy adult subjects that brexanolone use did not prolong the QT interval to any clinically relevant extent when administered at 1.9-times the exposure occurring at the highest recommended infusion rate (90 mcg/kg/hour).

Mechanism of Action · 1 件

Brexanolone is a neuroactive steroid that occurs naturally (referred to as natural allopregnanolone) in the body when the female sex hormone progesterone is metabolized. This steroid compound is also believed to exhibit activity as a barbiturate-like, positive allosteric modulator of both synaptic and extrasynaptic GABA(a) receptors. In doing so, brexanolone can enhance the activity of GABA at such receptors by having GABA(a) receptor calcium channels open more often and for longer periods of time. Furthermore, it is believed that brexanolone elicits such action on GABA(a) receptors at a binding site that is distinct from those associated with benzodiazepines. Concurrently, GABA is considered the principal inhibitory neurotransmitter in the human body. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons, like those involved in neuronal pathways that may be in part responsible for eliciting certain traits of PPD like stress, anxiety, etc. Postpartum depression (PPD) is a mood disorder that can affect women after childbirth. Women with PPD experience feelings of extreme sadness, anxiety, and exhaustion that can make it difficult or even dangerous for them to perform various daily activities or care for themselves or for others, including newborn. Although the exact pathophysiology of PPD remains unknown, it is believed that altered profiles and rapid, unpredictable fluctuations in the blood concentrations of neuroactive steroids like endogenous brexanolone (among others), GABA, and GABA receptors occur in women who are at risk of PPD after childbirth. In particular, within the context of PPD, it is proposed that endogenous brexanolone levels can quickly drop or fluctuate variedly after childbirth and that GABA(a) receptor levels and expression are decreased and down-regulated throughout pregnancy. Such fluctuations and decreases may consequently leave women susceptible to the possibility of PPD. As a medication, synthetic brexanolone can subsequently facilitate a return of positive allosteric modulator GABA(a) modulation while GABA(a) receptor levels and expression gradually return to normal in the time following postpartum. As such, studies suggest the potential for the development of brexanolone as a new mechanism for treatment of PPD that is directly related to the underlying pathophysiology as opposed to many other antidepressant medications whose pharmacological actions are usually entirely unrelated.

Biological Half-LifeThe terminal half-life observed for brexanolone is approximately 9 hours.
Metabolism/Metabolites · 1 件

Brexanolone is extensively metabolized by non-cytochrome (CYP) based pathways by way of three main routes - keto-reduction (via aldo-keto reductases), glucuronidation (via UDP-glucuronosyltransferases), and sulfation (via sulfotransferases). Three predominant circulating metabolites result from such metabolic pathways and they are all pharmacologically inactive and ultimately do not contribute to the overall efficacy of the medication.

FDA Pharmacological Classification · 5 件

S39XZ5QV8Y

BREXANOLONE

Established Pharmacologic Class [EPC] - Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

Mechanisms of Action [MoA] - GABA A Receptor Positive Modulators

Brexanolone is a Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator. The mechanism of action of brexanolone is as a GABA A Receptor Positive Modulator.

MeSH Pharmacological Classification · 3 件

Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Endogenous compounds or drugs that affect neuronal excitability through modulation of specific ionotropic receptors (e.g., GABA-A RECEPTORS). Endogenous neurosteroids are steroid hormones de novo synthesized by neurons and glial cells from steroid metabolite precursors (e.g., PREGNENOLONE).

Absorption, Distribution and Excretion · 4 件

It has been determined that brexanolone has a low oral bioavailability of approximately <5% in adults, which suggests infant exposure would also be expected to be low.

Following the administration of radiolabeled brexanolone, it was observed that 47% of the administrated dose was recovered largely as metabolites in the feces and 42% in urine, where less than 1% as recovered as unchanged brexanolone.

The volume of distribution documented for brexanolone is approximately 3 L/kg, a value which suggests relatively extensive distribution into tissues.

The total plasma clearance determined for brexanolone is approximately 1 L/h/kg.

Cellular LocationsExtracellular
応用分野 · 2 件

説明Allopregnanolone is an endogenous inhibitory pregnane neurosteroid that is synthesized from progesterone . It acts as a positive allosteric modulator of GABAA receptors at nM concentrations (exhibiting the greatest potentiation at isoforms containing δ subunits) and of GABAC receptors at μM concentrations. Allopregnanolone displays effects similar to other GABAA receptor potentiators such as benzodiazepines, including potent anticonvulsant, anxiolytic, and sedative activity.

使用(3α)-Allopregnanolone acts as a GABAA receptor positive allosteric modulator. (3α)-Allopregnanolone is a metabolite of Progesterone (P755900). (3α)-Allopregnanolone is a neuroactive steroid present in the blood and also the brain.

関連反応

18 件
反応記録を作成
HRID 232793 の反応式
HRID 232793反応物として
HRID 232797 の反応式
HRID 232797生成物として
HRID 232798 の反応式
HRID 232798反応物として
HRID 232799 の反応式
HRID 232799反応物として
HRID 232803 の反応式
HRID 232803反応物として
HRID 232804 の反応式
HRID 232804反応物として
HRID 232808 の反応式
HRID 232808反応物として
HRID 247813 の反応式
HRID 247813生成物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート